שולי רווח נקי Nanobiotix SA (NBTX)

לוגו גרפי של Nanobiotix Group (NBTX)

Stable cash flow from partner payments offsets R&D expenses, as confirmed by the adjusted net profit margin. The current -632.60 determines the magnitude of the efficiency metric. Nanobiotix S.A. revenues rely on the commercialization of NBTXR3 nanoparticles to enhance tumor therapy, while the scientific team actively expands the application of the innovative platform through strategic alliances.

רווחיות מכירות לפי רווח נקי Nanobiotix S.A. (NBTX): לתקופה 04.07.2022 - 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Nanobiotix Corp (NBTX)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח ראשוני של החברה:Nanobiotix S.A.
מוצר המיוצר על ידי Nanobiotix SA

To separate sustainable business from speculative assets, capital evaluates the net profit margin per dollar of revenue, which reflects the ability of Nanobiotix S.A. (NBTX) to retain earnings after all expenses. By analyzing the sales efficiency metric based on net profit on GURU.Markets, an investor can discern the financial stability of a company whose oncological nanotechnologies are independent of economic cycles and are determined solely by regulatory success.